Cancer Immunotherapy Market By Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy, Cytokine-based Immunotherapy, Oncolytic Virus Therapy, Others), By Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Others), By Route of Administration (Intravenous, Oral, Intratumoral, Subcutaneous, Others), By Biomarker Type (PD-L1 Expression, Microsatellite Instability, Tumor Mutational Burden, BRCA Mutation, HER2 Expression, Others), and By End User (Hospitals, Cancer Research Centers, Specialty Clinics, Ambulatory Surgical Centers, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Cancer Immunotherapy Market in the coming years?

The Cancer Immunotherapy Market accounted for USD 124.87 Billion in 2024 and USD 138.26 Billion in 2025 is expected to reach USD 382.78 Billion by 2035, growing at a CAGR of around 10.72% between 2025 and 2035. The cancer immunotherapy market is the market segment interested in the treatment of cancer by using the immune system of the body to counteract the cancer. Such therapies are immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and monoclonal antibodies. Immunotherapy provides a precision treatment option for cancer with fewer side effects than other, more conventional therapies, such as chemotherapy and radiation. The market is expanding at a vigorous rate because of technological breakthroughs in life science and oncology, growth in incidences of diseases such as cancer, and the desire to treat patients based on an individual. It has become part and parcel of enhancing survival and improving the lives of cancer patients globally.

What do industry experts say about the Cancer Immunotherapy market trends?

“Cancer immunotherapy has revolutionized oncology by leveraging the patient’s immune system to fight cancer. It represents one of the most significant paradigm shifts in cancer treatment in decades.”

• Dr. James P. Allison, PhD – Nobel Laureate, Chair of Immunology, MD Anderson Cancer Center

“CAR-T cell therapy has opened new frontiers in treating hematologic cancers and is now expanding into solid tumors, providing hope for previously untreatable conditions.”

• Dr. Carl June, MD – Director, Center for Cellular Immunotherapies, University of Pennsylvania

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Cancer Immunotherapy market?

How does biotechnology advancement contribute to cancer immunotherapy growth?

The rapid development of advancements in biotechnology has strongly contributed to the upsurge in cancer immunotherapy, as it offers the opportunity of specific immunisation of cancer cells in the form of engineered antibodies, custom-designed vaccines, and cell-based mediators such as CAR-T cells. Biotechnology enables the manipulation of immune cells in a manner to better recognise and attack tumour cells, resulting in a better response to therapy and decreased side effects of therapy, as compared with conventional cancer therapeutics.

The National Cancer Institute (NCI) has indicated that the amount of funding for cancer immunotherapy research has grown exponentially, with more than 3.6 billion dollars being devoted to cancer research in FY 2022, a significantly high portion of which goes to cancer immunotherapy initiatives. The FDA has approved more than 100 biologics to treat cancer as of 2023, most of which can be considered immunotherapy drugs.

Institutions of higher learning, such as MD Anderson Cancer Centre and Stanford University, have remained at the forefront of cutting-edge trials employing novel biotechnological blueprints, such as CRISPR and RNA-based technologies. These advancements indicate the fact that biotechnology is not only the prerequisite of innovation but also the catalyst of clinical translation of immunotherapies, which promotes market growth.

Can rising prevalence of cancer boost immunotherapy market expansion?

One of the reasons why the cancer immunotherapy business is experiencing growth is its increased rate. As stated by the World Health Organisation (WHO), cancer is considered one of the major causes of death in the world, with about ten million deaths reported in the year 2020. The rising prevalence of different types of cancer in the world has escalated demand to seek out new methods of treatment that can be more than conventional techniques, like chemotherapy and radiation. Immunotherapy that utilises the immune system of the body to fight cancerous cells has received a lot of attention, given the possibility to positively affect patient outcomes.

According to the National Cancer Institute (NCI), there is massive spending on immunotherapy research, with a budget of more than one point seven billion dollars ($1.7 billion) in 2023 aimed at developing and advancing the treatment. This cancer burden, coupled with good governmental as well as academic support, is contributing to the growth of the immunotherapy market significantly.

Are there regulatory challenges slowing down market product approvals?

Regulatory issues have been found to greatly influence cancer immunotherapy products' finding their way to the market. The approval process of biologics by the FDA in the U.S. is a rigorous process of clinical testing that aligns with the standards of safety and efficacy and prolongs the delivery timelines. The National Cancer Institute has found that clinical trial activation may take months longer than usual since complex Institutional Review Board (IRB) reviews and manufacturing compliance with proper Good Manufacturing Practice (GMP) standards are necessary. Whereas IND applicants can expect a response within 30 days, the FDA is likely to request additional data with immunotherapies that can extend the eligibility process.

A study done by the National Institutes of Health concluded that most drugs approved in oncology used between the years 2000 and 2020 were not supported by randomized controlled trials, and fewer were shown to bring long-term survival benefits. There are expedited approval routes developed to allow quick approval of therapeutics and have brought about post-approval withdrawal when therapeutics' confirmatory trials have not been insightful regarding benefits. These regulatory complexities delay the approval of radical immunotherapies, which influence the access of patients and market development.

Is personalization of therapies creating new market expansion paths?

The concept of personalized medicines is also adding immensely to the emerging market trends within the cancer immunotherapy landscape, as it means that therapies can now be designed based on specific genetic alterations of patients, immune status, and the tumor microenvironment. NCI states that biomarkers have been used to identify patients who respond well to immunotherapy and, thus, enhance patient response and outcomes, which may promote broader use. Immune checkpoint inhibitors are more effective than using a single agent in patients with specific sequences, such as the expression of PD-L1, thus allowing oncologists to individualize therapies.

The U.S. National Institutes of Health (NIH) cites a growing investment in the area of immunotherapy research as evidence of government interest in personalized cancer therapy. Through this selective approach, unnecessary exposure to ineffective therapy by patients, providers, and products is reduced, costs are minimized, and the survival rate is improved, thereby increasing the market capture by tapping more providers and patients. Personalized immunotherapies also lead to innovation, creating new areas of growth for companies and partnerships across biopharma and academia, which sought to develop next-generation immuno-oncology therapies.

Will emerging nanotechnology enhance delivery mechanisms in treatments?

Nanotechnology is on the verge of transforming cancer immunotherapy, facilitating highly localized and efficient delivery of cancer-killing, immune-activating agents to tumour bodies. It is perceived that nanoparticles enhance the stability and bioavailability of highly delicate immunotherapeutic agents like microRNA and monoclonal antibodies to protect them against early breakdowns.

Nanocarriers use the enhanced permeability and retention characteristics within tumours, so they accumulate in cancer tissues with low systemic toxicity. Areas of focus at leading universities indicate that nanoparticle platforms can be designed to degrade under conditions in the tumor environment, such as the upregulation of specific ligands, when they can be used to deliver drugs with greater specificity.

The nanocarriers can also be used as multifunctional, as they can synergistically deliver checkpoint inhibitors and adjuvants, better extending the activation of the immune system and preventing tumour immune evasion. These developments, according to the National Institutes of Health, promise better patient outcomes because of enhanced immune-cell infiltration of tumors and reduced side effects. Overall, nanotechnology-based delivery represents a potential emerging area of expertise to make cancer immunotherapies more effective and safe.

What are the key market segments in the Cancer Immunotherapy industry?

Based on the Therapy type, the Cancer Immunotherapy Market is classified into Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy, Cytokine-based Immunotherapy, Oncolytic Virus Therapy, and Others. Some of the different types of therapies available in the cancer immunotherapy market include monoclonal antibodies, which represent the dominant segment. They are on their rise due to their demonstrated clinical efficacy, extensive applicability in a wide variety of cancer types, and effective regulatory approval status.

Monoclonal antibodies have a precise attack on particular antigens on cancerous cells with minimal side effects as opposed to conventional methods. Drugs such as rituximab, trastuzumab, and bevacizumab are some of the key drugs that have become blockbusters, ensuring market superiority. Further, the advent of recently re-engineered antibodies and antibody cocktail combinations supports their application in immunomodulation in oncology.

Based on the Cancer Type, the Cancer Immunotherapy Market is classified into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Blood Cancers, and Others. The most prevailing segment of the cancer immunotherapy market is the lung cancer segment. It enjoys such prominence due to a large incidence and mortality globally, leading to technological investments in its relation to research and treatment. Other strategies, such as immunotherapies (e.g., immune checkpoint inhibitors, Keytruda, and Opdivo), have been remarkable in treating non-small cell lung cancer (NSCLC), and this new therapeutic approach has provided more striking survival rates.

The advanced-stage lung cancer that lacks effective treatment, necessitating the urgency of effective therapies, has catalysed the process of regulatory approval and adoption. This has seen lung cancer remain the market leader in the immunotherapy market.

Which regions are leading the Cancer Immunotherapy market, and why?

The North American cancer immunotherapy market is dominant due to several reasons. The region has a well-developed healthcare infrastructure and much investment in biomedical research, which allows the development and introduction of new promising treatments using immunotherapies. The domination of large pharmaceuticals and centres of cancer research helps to consistently introduce innovations and clinical trials. Moreover, the tremendous awareness of immunotherapy and its potential among the patients and healthcare practitioners creates a high level of demand. More friendly regulatory policies and reimbursement systems also enable faster access to new therapies on the market.

The growing prevalence of cancer and escalating healthcare spending in North America further drive the growth of this market, making it a global leader in this market. The already solid relationships between academia and industry players expedite the innovation and commercialisation of new therapies. The increased focus on personalised medicine also lies in favour of the individualised immunotherapy, which has gained wide popularity in the region.

The Asia Pacific cancer immunotherapy market is growing because of a number of reasons. The increasing cancer incidence, especially in China, Japan, and India, has increased demand to find new treatment methods. Further, growing investments in healthcare infrastructure and proliferating outreach efforts on the part of the government towards cancer treatment have ramped up market expansion. Another advantage that the region enjoys is a large pool of patients to conduct clinical trials, as well as rapid usage of advanced therapy.

The growing awareness of the benefits of immunotherapy, and the betterment of reimbursement policy, is contributing to the penetration of the market. Moreover, the well-developed biotechnology industry in the Asia Pacific and the relationships between the international pharmaceutical industries and the local companies provide the industry with strong innovation and access.

The presence of competent medical personnel and the development of technologies in diagnostics add more weight to recovery levels. In general, the active healthcare environment and economic expansions in the region are the main factors that contribute to its superiority in the cancer immunotherapy industry.

What does the competitive landscape of the Cancer Immunotherapy market look like?

The cancer immunotherapy market is competitive because of the major pharmaceutical companies' strategic alliances and constant innovation. Other key players, including Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca, and Novartis, are actively developing their immunotherapy portfolio in the research of the field incorporated with checkpoint inhibitors, CAR-T therapies, and personalised cancer vaccines.

Recent evolutions include the extension by Merck of indications of its PD-1 inhibitor and the acquisition by Bristol-Myers Squibb, in the form of MyoKardia, to strengthen its oncology pipeline. In addition, characteristically, other companies, such as Gilead Sciences and its acquisition of Kite Pharma, have improved their portfolio by becoming strong in the field of CAR-T. Other companies like Adaptimmune Therapeutics are also on the rise with T-cell therapies.

A current trend in the market sees the market moving towards combination therapies and the next-generation immune modulators, making the market a dynamic place where innovation and strategic cooperation are the main factors to stay on the competitive edge. Besides, there is increasing effectiveness in treatment through biomarker-driven selection of patients in addition to the increasing investments in biotech startups that bring innovative measures in cancer immunotherapy.

Cancer Immunotherapy Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Cancer Immunotherapy industry?

• In March 2025, Canon Medical Systems USA announced FDA clearance of the Adora DRFi and its immediate availability in the U.S. market. The system combined radiography and fluoroscopy with a rotating ceiling design. Its PositionAnywhere technology allowed the X-ray tube and detector to move independently to adjust to the patient.
• In January 2025, at AOCR 2025, Philips launched the AI-enabled CT 5300 as part of their Smart Imaging portfolio. The CT 5300 included advanced AI tools for image reconstruction, cardiac motion correction, and improved workflows. Philips also showcased its BlueSeal wide-bore MRI, which used only 0.5% of the helium required by traditional magnets, emphasizing efficiency and sustainability.

Report Coverage:

By Therapy Type

• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Cancer Vaccines
• Adoptive Cell Therapy
• Cytokine-based Immunotherapy
• Oncolytic Virus Therapy
• Others

By Cancer Type

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Blood Cancers
• Others

By Route of Administration

• Intravenous
• Oral
• Intratumoral
• Subcutaneous
• Others

By Biomarker Type

• PD-L1 Expression
• Microsatellite Instability
• Tumor Mutational Burden
• BRCA Mutation
• HER2 Expression
• Others

By End User

• Hospitals
• Cancer Research Centers
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Bristol-Myers Squibb
• Merck & Co., Inc.
• Roche Holding AG
• AstraZeneca plc
• Novartis AG
• Pfizer Inc.
• Amgen Inc.
• Johnson & Johnson
• Regeneron Pharmaceuticals, Inc.
• Gilead Sciences, Inc.
• Moderna, Inc.
• Bluebird Bio, Inc.
• Seagen Inc.
• CureVac AG
• Adaptimmune Therapeutics plc

Frequently Asked Questions (FAQs)